Grufity logoGrufity logo

CTLT

52.25USD+0.02(+0.04%)Market Closed

Catalent Inc

Market Summary

USD52.25+0.02Market Closed
0.04%

CTLT Alerts

CTLT Stock Price

RSI Chart

Valuation

Market Cap

11.9B

Price/Earnings

22.94

Price/Sales

2.47

Price/Cashflow

27.12

MarketCap/EBT

19.68

Price/Sales

Profitability

EBT Margin

12.53%

Return on Equity

10.82%

Return on Assets

4.94%

Fundamentals

Revenue

Revenue (TTM)

4.8B

Revenue Y/Y

-0.29%

Revenue Q/Q

-22.16%

Earnings

Earnings (TTM)

426.0M

Earnings Y/Y

-100%

Earnings Q/Q

-100%

Price Action

52 Week Range

40.69130.97
(Low)(High)

Last 7 days

26.2%

Last 30 days

16.4%

Last 90 days

-40.3%

Trailing 12 Months

-59.1%

Financial Health

Current Ratio

2.72

Debt/Equity

0.87

Debt/Cashflow

0.11

Investor Care

Shares Dilution (1Y)

5.13%

Diluted EPS (TTM)

2.35

Peers (Alternatives to Catalent)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
459.8B
96.0B
5.64% 16.86%
24
4.79
5.02% 7.14%
342.0B
29.2B
5.87% 53.25%
60.08
11.76
5.34% 1.02%
266.2B
99.7B
9.09% -0.90%
9.08
2.63
43.92% 53.21%
255.3B
57.2B
10.70% 54.15%
15.4
4.47
35.88% 197.59%
163.4B
46.7B
4.75% 50.97%
24.47
3.5
2.79% 223.53%
MID-CAP
5.5B
4.4B
-19.59% -9.60%
-46.93
1.26
1.80% 57.67%
SMALL-CAP
1.9B
628.4M
27.93% -51.99%
-4.08
3.1
64.35% -18.14%
1.9B
659.0M
9.23% 20.30%
32.36
2.95
16.78% -53.92%
1.5B
-
32.82% -58.59%
-0.54
1.95
-4.11% -144.36%
1.2B
112.7M
16.50% -21.36%
-10.75
7.76
-54.94% 40.20%
1.1B
3.1M
16.81% -54.64%
-3.57
108.75
-77.09% -12.24%
1.0B
23.5M
9.62% 31.13%
-12.31
166.87
243.57% -1.04%
945.9M
373.2M
0.99% -19.37%
4.56
2.34
-0.39% -38.45%
283.2M
49.7M
-11.83% -51.92%
-8.71
5.67
28.95% 32.80%
68.8M
2.6B
-43.99% -88.43%
-0.03
0.02
-13.88% -4855.92%

Financials for Catalent

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-0.1%4,8254,8284,7034,4844,177
Gross Profit-4.0%1,5741,6401,5911,5341,427
  S&GA Expenses1.5%857844802768705
  R&D Expenses-4.3%2223242120
Earnings Before Taxes-16.5%505605615756750
Net Income-17.9%426519513604595
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-2.9%10,20510,50710,32210,20310,183
  Current Assets-7.5%2,6982,9163,0252,9743,931
    Cash Equivalents-37.4%2814497868491,969
  Inventory4.3%732702676688622
  Net PPE1.3%3,1673,1272,8202,7272,581
  Goodwill-2.6%2,9293,0063,0123,0262,531
Liabilities-3.6%5,5055,7125,6905,7225,803
  Current Liabilities-12.0%9431,0721,0461,0451,096
  Long Term Debt-1.8%4,0984,1714,1574,1914,225
Shareholder's Equity-2.0%4,7004,7954,6324,4814,021
  Retained Earnings0%538538350209114
  Additional Paid-In Capital0.4%4,6494,6304,6154,234-
Accumulated Depreciation0.8%1,3581,3471,3081,2151,215
Shares Outstanding4.7%179171171--
Float-21,840----
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-58.1%184439504441446
  Share Based Compensation-3.7%5254555354
Cashflow From Investing2.7%-1,833.00-1,884.00-1,703.00-1,594.00-665.00
Cashflow From Financing-97.8%231,0311,0131,1821,174

Risks

What is the probability of a big loss on CTLT?

58.9%


Probability that Catalent stock will be more than 20% underwater in next one year

49.2%


Probability that Catalent stock will be more than 30% underwater in next one year.

4.2%


Probability that Catalent stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CTLT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Catalent was unfortunately bought at previous high price.

Returns

Cumulative Returns on CTLT

9.5%


7-Year Cumulative Returns

6.1%


5-Year Cumulative Returns

0.6%


3-Year Cumulative Returns

What are the long-term rolling returns for CTLT?

FIve years rolling returns for Catalent.

Which funds bought or sold CTLT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-29
Bridgefront Capital, LLC
SOLD OFF
-100
-236,000
-
-%
2022-11-23
Eagle Bay Advisors LLC
REDUCED
-64.5
-119,682
39,000
0.02%
2022-11-23
Toroso Investments, LLC
ADDED
5.4
-108,000
264,000
0.01%
2022-11-22
CVA Family Office, LLC
REDUCED
-73.68
-8,000
2,000
-%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
1,208,000
1,208,000
0.01%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-1.09
-10,064,000
20,163,000
0.03%
2022-11-21
Integrated Investment Consultants, LLC
ADDED
1.8
-219,000
480,000
0.19%
2022-11-18
National Pension Service
REDUCED
-6.3
-10,157,000
18,758,000
0.04%
2022-11-17
CENTRAL TRUST Co
UNCHANGED
-
-4,000
7,000
-%
2022-11-17
M&T Bank Corp
REDUCED
-14.59
492,000
1,207,000
-%

1–10 of 46

Latest Funds Activity

Are funds buying CTLT calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own CTLT

Catalent News

MarketBeat

Short Interest in Catalent, Inc. (NYSE:CTLT) Decreases By 11.8%.2 hours ago

Yahoo Finance

CTLT Fair Value

Recent SEC filings of Catalent

View All Filings
Date Filed Form Type Document
Nov 22, 2022
8-K
Current Report
Nov 02, 2022
4
Insider Trading
Nov 01, 2022
10-Q
Quarterly Report
Nov 01, 2022
8-K
Current Report
Oct 31, 2022
4
Insider Trading
Oct 31, 2022
4
Insider Trading
Oct 31, 2022
4
Insider Trading
Oct 31, 2022
4
Insider Trading
Oct 31, 2022
4
Insider Trading
Oct 31, 2022
4
Insider Trading

Latest Insider Trading transactions for CTLT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-10-31
Grippo Michael J
SOLD
-161,349
65.83
-2,451
SVP, Strategy & Corp. Dev.
2022-10-27
Zippelius Peter
ACQUIRED
-
-
4,149
-
2022-10-27
LUCIER GREGORY T
ACQUIRED
-
-
4,149
-
2022-10-27
Crane Rosemary A
ACQUIRED
-
-
4,149
-
2022-10-27
STAHL JACK L
ACQUIRED
-
-
4,149
-
2022-10-27
Kreuzburg Christa
ACQUIRED
-
-
4,149
-
2022-10-27
Balachandran Madhavan
ACQUIRED
-
-
4,149
-
2022-10-27
GREISCH JOHN J
ACQUIRED
-
-
4,149
-
2022-10-27
MOREL DONALD E JR
ACQUIRED
-
-
4,149
-
2022-10-27
Barber Michael J
ACQUIRED
-
-
4,149
-

1–10 of 50

John R. Chiminski
17300
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

CTLT Income Statement

2022-09-30
Consolidated Statements of Operations - USD ($)
$ in Millions
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]  
Net revenue$ 1,022.0$ 1,025.0
Cost of sales764.0701.0
Gross margin258.0324.0
Selling, general, and administrative expenses196.0183.0
Payments for (Proceeds from) Businesses and Interest in Affiliates[1]0.0(1.0)
Other Cost and Expense, Operating2.04.0
Operating earnings60.0138.0
Interest expense, net32.026.0
Other (income)/expense, net[2]25.09.0
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total3.0103.0
Income tax expense3.010.0
Net earnings/(loss)0.093.0
Participating Securities, Distributed and Undistributed Earnings (Loss), Basic0.09.0
Net Income (Loss) Available to Common Stockholders, Basic$ 0.0$ 84.0
Earnings Per Share, Basic$ 0$ 0.49
Earnings Per Share, Diluted$ 0$ 0.49
[1]Gain on sale of subsidiary for the three months ended September 30, 2021 was due to the sale of the facility in Woodstock, Illinois and the associated business
[2]Other expense, net during the three months ended September 30, 2022 includes foreign currency remeasurement losses/gains.Other expense, net during the three months ended September 30, 2021 includes financing charges related to the Company’s Incremental Term B-3 Loans and foreign currency remeasurement losses/gains.

CTLT Balance Sheet

2022-09-30
Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2022
Jun. 30, 2022
Current assets:  
Cash and cash equivalents$ 281$ 449
Trade receivables, net9891,051
Inventories732702
Prepaid expenses and other632625
Marketable Securities6489
Total current assets2,6982,916
Property, plant, and equipment, net3,1673,127
Other assets:  
Goodwill2,9293,006
Other intangibles, net1,0171,060
Deferred Income Tax Assets, Net4549
Other Assets, Noncurrent349349
Total assets10,20510,507
Current Liabilities:  
Debt, Current10631
Accounts payable379421
Other accrued liabilities458620
Total current liabilities9431,072
Long-term obligations, less current portion4,0984,171
Pension liability98103
Deferred Income Taxes214202
Other liabilities152164
Total liabilities5,5055,712
Temporary Equity, Carrying Amount, Attributable to Parent$ 0$ 0
Common Stock, Par or Stated Value Per Share$ 0.01$ 0.01
Common Stock, Shares Authorized1,000,000,0001,000,000,000
Common Stock, Value, Outstanding$ 2$ 2
Preferred Stock, Value, Outstanding00
Additional paid in capital4,6744,649
Accumulated deficit538538
Accumulated other comprehensive income/(loss)(514)(394)
Total shareholders' equity4,7004,795
Total liabilities, redeemable preferred stock, and shareholders’ equity$ 10,205$ 10,507
Common stock, shares issued (shares)180,000,000179,000,000